Iteos <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Delisting from Nasdaq Following Merger Completion
iTeos Therapeutics Inc. has announced a significant regulatory development following its merger with Concentra Biosciences, LLC. The company has completed a tender offer and subsequently become a wholly owned subsidiary of Concentra. As part of this transition, iTeos has notified The Nasdaq Stock Market of the merger's consummation and requested the suspension of trading of its shares, effective from August 29, 2025. Additionally, the company intends to delist its shares from Nasdaq and deregister them under the Securities Exchange Act of 1934. This move includes filing a Certification and Notice of Termination of Registration on Form 15, seeking to terminate the shares' registration and suspend reporting obligations under Sections 13 and 15(d) of the Exchange Act. The regulatory changes mark a significant shift in the company's public status post-merger.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iteos Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-192031), on August 29, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。